With TheraTears, Prestige Consumer Sees Way To Boost Guidance Despite COVID, Cost Uncertainties
More than 17% growth in consumer health product sales in latest quarter on top of adding TheraTears brands to its lineup at start of current quarter outweighs potential headwinds from costs and changes in consumer spending, Prestige Consumer executives say.
You may also be interested in...
Retailer and consumer stockpiling in fear of supply chain disruptions drive double digit consumption growth for Prestige Consumer Healthcare’s Dramamine, Nix, Hydralyte and cough/cold brands. Brands drove total sales up 10.5% excluding impact of Akorn, to $12.4m in latest quarter.
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.